ArticleCureus2026
Association of Age and Spherical Equivalent With Differences in Cycloplegic Refractive Effects Between Cyclopentolate and Atropine.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAmblyopia and strabismus are common visual impairments linked to functional and social consequences in children. In this retrospective study, we compared the cycloplegic effects of two cycloplegic eye drops, cyclopentolate and atropine, and examined whether age and initial spherical equivalent (SE) influenced these effects. MATERIALS AND
methodsWe retrospectively reviewed electronic medical records from Kozawa Eye Hospital and Diabetes Center between 2001 and 2021. The primary outcome was the difference in SE between atropine and cyclopentolate (atropine minus cyclopentolate). As both eyes from the same patient could be included, multivariable generalized estimating equations (GEE) with an exchangeable working correlation structure clustered by patient identifier were used. Additional analyses included the Wilcoxon signed-rank test, Bland-Altman analysis, and Yeo-Johnson transformation of the outcome before multivariable modeling.
resultsThe analysis included 186 eyes from 93 patients (median age, 6.00 years). Median SE was 2.47 D under cyclopentolate and 2.75 D under atropine, with a significant paired difference (Wilcoxon signed-rank test, p < 0.001). Bland-Altman analysis showed a mean difference of +0.42 D, with 95% limits of agreement from -0.44 to +1.28 D, and no significant proportional bias (slope = -0.016, p = 0.300). In the multivariable GEE model, older age was associated with a smaller atropine-cyclopentolate difference (β = -0.034, 95% confidence interval (CI): -0.065 to -0.003, p = 0.031), and higher initial SE was also associated with a smaller difference (β = -0.032, 95% CI: -0.060 to -0.004, p = 0.023). Sex and eye laterality were not significantly associated with the difference.
conclusionAtropine produced a stronger refractive effect than cyclopentolate in this pediatric cohort. The atropine-cyclopentolate difference was smaller in older patients and in eyes with higher initial SE, supporting consideration of age and baseline refractive status when selecting cycloplegic agents in pediatric patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.